BCRX logo

BioCryst Pharmaceuticals (BCRX) Cash From Investing

Annual CFI

$52.59 M
+$184.09 M+140.00%

December 31, 2024

Summary

Performance

1-Year Change

+140%

3-Year Change

+232.78%

5-Year Change

-32.52%

15-Year Change

+181.36%

BCRX Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

89.52%
BCRX annual cash flow from investing activities is higher than 89.52% of companies in Healthcare sector

High & Low

All-time High

$77.93 M
BCRX annual cash flow from investing activities is currently -32.52% below its historical high of $77.93 million

3-Year Low

-$131.50 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
BCRX previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
BCRX next annual earnings announcement has not yet been scheduled

OtherBCRXcash flowmetrics:

Annual CFF

-$5.76 M
BCRX annual cash flow from financing activities is -$5.76 million

Annual CFO

-$52.02 M
BCRX annual cash flow from operations is -$52.02 million

Annual FCF

-$53.14 M
BCRX annual free cash flow is -$53.14 million

Annual CAPEX

$1.12 M
BCRX annual capital expenditures is $1.12 million

Quarterly CFI

$17.80 M
+$9.31 M+109.65%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+260.04%

5-Year Change

+9.45%

BCRX Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

86.85%
BCRX quarterly cash flow from investing activities is higher than 86.85% of companies in Healthcare sector

High & Low

All-time High

$77.22 M
BCRX quarterly cash flow from investing activities is currently -76.95% below its historical high of $77.22 million

3-Year Low

-$107.11 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
BCRX previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 6, 2025
BCRX next earnings announcement is scheduled for May 6, 2025

OtherBCRXcash flowmetrics:

Quarterly CFF

-$4.02 M
BCRX quarterly cash flow from financing activities is -$4.02 million

Quarterly CFO

-$5.21 M
BCRX quarterly cash flow from operations is -$5.21 million

Quarterly FCF

-$5.89 M
BCRX quarterly free cash flow is -$5.89 million

Quarterly CAPEX

$675.00 K
BCRX quarterly capital expenditures is $675.00 thousand

TTM CFI

$52.59 M
+$46.27 M+731.77%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

+232.78%

5-Year Change

-32.52%

BCRX TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

89.81%
BCRX TTM cash flow from investing activities is higher than 89.81% of companies in Healthcare sector

High & Low

All-time High

$77.93 M
BCRX TTM cash flow from investing activities is currently -32.52% below its historical high of $77.93 million

3-Year Low

-$216.57 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
BCRX previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 6, 2025
BCRX next earnings announcement is scheduled for May 6, 2025

OtherBCRXcash flowmetrics:

TTM CFF

-$5.76 M
BCRX TTM cash flow from financing activities is -$5.76 million

TTM CFO

-$52.02 M
BCRX TTM cash flow from operations is -$52.02 million

TTM FCF

-$53.14 M
BCRX TTM free cash flow is -$53.14 million

TTM CAPEX

$1.12 M
BCRX TTM capital expenditures is $1.12 million

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

BCRX Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+140.0%0.0%0.0%
3 y3 years+232.8%+260.0%+232.8%
5 y5 years-32.5%+9.4%-32.5%

BCRX Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+140.0%-77.0%+116.6%at high+124.3%
5 y5-year-32.5%+140.0%-77.0%+116.6%-32.5%+124.3%
alltimeall time-32.5%+140.0%-77.0%+116.6%-32.5%+124.3%

BioCryst Pharmaceuticals Cash From Investing History

DateAnnualQuarterlyTTM
Dec 2024
$52.59 M(-140.0%)
$17.80 M(+109.6%)
$52.59 M(+731.8%)
Sep 2024
-
$8.49 M(-446.6%)
$6.32 M(-69.8%)
Jun 2024
-
-$2.45 M(-108.5%)
$20.95 M(+379.8%)
Mar 2024
-
$28.76 M(-201.0%)
$4.37 M(-103.3%)
Dec 2023
-$131.50 M(+2.5%)
-$28.47 M(-223.2%)
-$131.50 M(+409.5%)
Sep 2023
-
$23.12 M(-221.5%)
-$25.81 M(-78.2%)
Jun 2023
-
-$19.04 M(-82.2%)
-$118.47 M(-39.8%)
Mar 2023
-
-$107.11 M(-238.7%)
-$196.88 M(+53.5%)
Dec 2022
-$128.24 M(-911.4%)
$77.22 M(-211.0%)
-$128.24 M(-40.8%)
Sep 2022
-
-$69.54 M(-28.6%)
-$216.57 M(+55.5%)
Jun 2022
-
-$97.44 M(+153.3%)
-$139.28 M(+273.0%)
Mar 2022
-
-$38.47 M(+246.0%)
-$37.34 M(-336.3%)
Dec 2021
$15.80 M(-330.5%)
-$11.12 M(-243.5%)
$15.80 M(-67.3%)
Sep 2021
-
$7.75 M(+72.0%)
$48.34 M(+640.4%)
Jun 2021
-
$4.50 M(-69.3%)
$6.53 M(-324.6%)
Mar 2021
-
$14.67 M(-31.5%)
-$2.91 M(-57.6%)
Dec 2020
-$6.86 M(-108.8%)
$21.41 M(-162.9%)
-$6.86 M(-42.9%)
Sep 2020
-
-$34.06 M(+590.6%)
-$12.01 M(-126.4%)
Jun 2020
-
-$4.93 M(-146.0%)
$45.57 M(-37.4%)
Mar 2020
-
$10.72 M(-34.1%)
$72.78 M(-6.6%)
Dec 2019
$77.93 M(+1534.5%)
$16.26 M(-30.8%)
$77.93 M(+33.2%)
Sep 2019
-
$23.51 M(+5.5%)
$58.51 M(+129.7%)
Jun 2019
-
$22.28 M(+40.3%)
$25.47 M(+439.3%)
Mar 2019
-
$15.88 M(-601.5%)
$4.72 M(-1.0%)
Dec 2018
$4.77 M(-107.4%)
-$3.17 M(-66.8%)
$4.77 M(-109.6%)
Sep 2018
-
-$9.53 M(-721.3%)
-$49.45 M(+30.3%)
Jun 2018
-
$1.53 M(-90.4%)
-$37.96 M(-39.6%)
Mar 2018
-
$15.93 M(-127.8%)
-$62.85 M(-2.8%)
Dec 2017
-$64.64 M(-377.8%)
-$57.38 M(-3023.3%)
-$64.64 M(+278.4%)
Sep 2017
-
$1.96 M(-108.4%)
-$17.09 M(-688.9%)
Jun 2017
-
-$23.35 M(-265.2%)
$2.90 M(-91.6%)
Mar 2017
-
$14.13 M(-243.8%)
$34.70 M(+49.1%)
Dec 2016
$23.27 M(-229.3%)
-$9.83 M(-144.8%)
$23.27 M(-22.7%)
Sep 2016
-
$21.95 M(+159.9%)
$30.11 M(-401.8%)
Jun 2016
-
$8.44 M(+211.9%)
-$9.98 M(-12.1%)
Mar 2016
-
$2.71 M(-190.6%)
-$11.35 M(-37.0%)
Dec 2015
-$18.00 M(-55.0%)
-$2.99 M(-83.5%)
-$18.00 M(-73.6%)
Sep 2015
-
-$18.14 M(-356.5%)
-$68.11 M(+51.0%)
Jun 2015
-
$7.07 M(-279.1%)
-$45.10 M(+5.1%)
Mar 2015
-
-$3.95 M(-92.6%)
-$42.91 M(+7.3%)
Dec 2014
-$39.98 M(+1053.2%)
-$53.09 M(-1191.2%)
-$39.98 M(-468.6%)
Sep 2014
-
$4.87 M(-47.5%)
$10.85 M(+6205.8%)
Jun 2014
-
$9.27 M(-1005.8%)
$172.00 K(-102.6%)
Mar 2014
-
-$1.02 M(-54.8%)
-$6.56 M(+89.3%)
Dec 2013
-$3.47 M(-113.9%)
-$2.26 M(-61.1%)
-$3.47 M(-242.0%)
Sep 2013
-
-$5.81 M(-329.4%)
$2.44 M(-87.7%)
Jun 2013
-
$2.53 M(+22.2%)
$19.93 M(+29.2%)
Mar 2013
-
$2.07 M(-43.2%)
$15.42 M(-38.0%)
Dec 2012
$24.88 M(+119.9%)
$3.65 M(-68.8%)
$24.88 M(+34.2%)
Sep 2012
-
$11.68 M(-690.5%)
$18.55 M(-20.1%)
Jun 2012
-
-$1.98 M(-117.1%)
$23.21 M(+53.7%)
Mar 2012
-
$11.54 M(-528.7%)
$15.10 M(+33.4%)
Dec 2011
$11.32 M(+5021.3%)
-$2.69 M(-116.5%)
$11.32 M(-48.9%)
Sep 2011
-
$16.34 M(-262.0%)
$22.13 M(+83.6%)
Jun 2011
-
-$10.09 M(-230.0%)
$12.05 M(-50.6%)
Mar 2011
-
$7.76 M(-4.5%)
$24.39 M(>+9900.0%)
Dec 2010
$221.00 K(-101.7%)
$8.12 M(+29.8%)
$221.00 K(-100.5%)
Sep 2010
-
$6.26 M(+178.6%)
-$40.93 M(+4.5%)
Jun 2010
-
$2.25 M(-113.7%)
-$39.15 M(+21.4%)
Mar 2010
-
-$16.41 M(-50.3%)
-$32.24 M(+150.0%)
Dec 2009
-$12.89 M
-$33.03 M(-510.8%)
-$12.89 M(-141.5%)
Sep 2009
-
$8.04 M(-12.2%)
$31.03 M(+58.7%)
DateAnnualQuarterlyTTM
Jun 2009
-
$9.16 M(+212.3%)
$19.56 M(+44.0%)
Mar 2009
-
$2.93 M(-73.1%)
$13.58 M(+19.2%)
Dec 2008
$11.39 M(-175.8%)
$10.90 M(-417.4%)
$11.39 M(+223.0%)
Sep 2008
-
-$3.44 M(-208.0%)
$3.53 M(-120.9%)
Jun 2008
-
$3.18 M(+326.4%)
-$16.92 M(-23.7%)
Mar 2008
-
$746.00 K(-75.4%)
-$22.18 M(+47.5%)
Dec 2007
-$15.03 M(+20.4%)
$3.04 M(-112.7%)
-$15.03 M(+127.4%)
Sep 2007
-
-$23.88 M(+1046.3%)
-$6.61 M(-151.5%)
Jun 2007
-
-$2.08 M(-126.4%)
$12.83 M(+26.6%)
Mar 2007
-
$7.89 M(-31.1%)
$10.13 M(-181.1%)
Dec 2006
-$12.49 M(+8.5%)
$11.46 M(-358.2%)
-$12.49 M(-57.4%)
Sep 2006
-
-$4.44 M(-7.2%)
-$29.32 M(+46.1%)
Jun 2006
-
-$4.78 M(-67.6%)
-$20.07 M(-9.5%)
Mar 2006
-
-$14.73 M(+174.0%)
-$22.18 M(+92.7%)
Dec 2005
-$11.51 M(+305.9%)
-$5.38 M(-211.6%)
-$11.51 M(+417.3%)
Sep 2005
-
$4.82 M(-169.9%)
-$2.23 M(-66.3%)
Jun 2005
-
-$6.89 M(+69.7%)
-$6.62 M(-3816.3%)
Mar 2005
-
-$4.06 M(-203.8%)
$178.00 K(-106.3%)
Dec 2004
-$2.84 M(-133.9%)
$3.91 M(+811.9%)
-$2.84 M(-26.0%)
Sep 2004
-
$429.00 K(-524.8%)
-$3.84 M(-12.7%)
Jun 2004
-
-$101.00 K(-98.6%)
-$4.39 M(-626.9%)
Mar 2004
-
-$7.08 M(-342.9%)
$834.00 K(-90.0%)
Dec 2003
$8.37 M(-18.5%)
$2.91 M(-2358.1%)
$8.37 M(+18.6%)
Sep 2003
-
-$129.00 K(-102.5%)
$7.06 M(-23.6%)
Jun 2003
-
$5.13 M(+1019.4%)
$9.23 M(+84.3%)
Mar 2003
-
$458.00 K(-71.4%)
$5.01 M(-51.2%)
Dec 2002
$10.26 M(-49.6%)
$1.60 M(-21.8%)
$10.26 M(-9.8%)
Sep 2002
-
$2.05 M(+126.2%)
$11.38 M(-11.2%)
Jun 2002
-
$905.00 K(-84.2%)
$12.80 M(-18.6%)
Mar 2002
-
$5.71 M(+110.5%)
$15.72 M(-22.9%)
Dec 2001
$20.38 M(+1292.6%)
$2.71 M(-21.9%)
$20.38 M(+7.1%)
Sep 2001
-
$3.48 M(-9.1%)
$19.03 M(+10.6%)
Jun 2001
-
$3.82 M(-63.2%)
$17.20 M(+23.3%)
Mar 2001
-
$10.37 M(+663.4%)
$13.95 M(+853.0%)
Dec 2000
$1.46 M(-103.1%)
$1.36 M(-17.4%)
$1.46 M(-103.3%)
Sep 2000
-
$1.64 M(+186.4%)
-$44.09 M(-1.2%)
Jun 2000
-
$574.00 K(-127.2%)
-$44.64 M(-7.4%)
Mar 2000
-
-$2.11 M(-95.2%)
-$48.21 M(+1.1%)
Dec 1999
-$47.70 M(-922.4%)
-$44.20 M(-4118.2%)
-$47.70 M(+622.7%)
Sep 1999
-
$1.10 M(-136.7%)
-$6.60 M(+78.4%)
Jun 1999
-
-$3.00 M(+87.5%)
-$3.70 M(-254.2%)
Mar 1999
-
-$1.60 M(-48.4%)
$2.40 M(-58.6%)
Dec 1998
$5.80 M(-43.1%)
-$3.10 M(-177.5%)
$5.80 M(-42.0%)
Sep 1998
-
$4.00 M(+29.0%)
$10.00 M(+6.4%)
Jun 1998
-
$3.10 M(+72.2%)
$9.40 M(+2.2%)
Mar 1998
-
$1.80 M(+63.6%)
$9.20 M(-9.8%)
Dec 1997
$10.20 M(-137.5%)
$1.10 M(-67.6%)
$10.20 M(-169.9%)
Sep 1997
-
$3.40 M(+17.2%)
-$14.60 M(-3.3%)
Jun 1997
-
$2.90 M(+3.6%)
-$15.10 M(-30.7%)
Mar 1997
-
$2.80 M(-111.8%)
-$21.80 M(-19.9%)
Dec 1996
-$27.20 M(-1107.4%)
-$23.70 M(-917.2%)
-$27.20 M(+209.1%)
Sep 1996
-
$2.90 M(-176.3%)
-$8.80 M(-22.8%)
Jun 1996
-
-$3.80 M(+46.2%)
-$11.40 M(+418.2%)
Mar 1996
-
-$2.60 M(-50.9%)
-$2.20 M(-181.5%)
Dec 1995
$2.70 M(-131.4%)
-$5.30 M(-1866.7%)
$2.70 M(-64.0%)
Sep 1995
-
$300.00 K(-94.4%)
$7.50 M(-13.8%)
Jun 1995
-
$5.40 M(+134.8%)
$8.70 M(+480.0%)
Mar 1995
-
$2.30 M(-560.0%)
$1.50 M(-117.4%)
Dec 1994
-$8.60 M
-$500.00 K(-133.3%)
-$8.60 M(+6.2%)
Sep 1994
-
$1.50 M(-183.3%)
-$8.10 M(-15.6%)
Jun 1994
-
-$1.80 M(-76.9%)
-$9.60 M(+23.1%)
Mar 1994
-
-$7.80 M
-$7.80 M

FAQ

  • What is BioCryst Pharmaceuticals annual cash flow from investing activities?
  • What is the all time high annual CFI for BioCryst Pharmaceuticals?
  • What is BioCryst Pharmaceuticals annual CFI year-on-year change?
  • What is BioCryst Pharmaceuticals quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for BioCryst Pharmaceuticals?
  • What is BioCryst Pharmaceuticals quarterly CFI year-on-year change?
  • What is BioCryst Pharmaceuticals TTM cash flow from investing activities?
  • What is the all time high TTM CFI for BioCryst Pharmaceuticals?
  • What is BioCryst Pharmaceuticals TTM CFI year-on-year change?

What is BioCryst Pharmaceuticals annual cash flow from investing activities?

The current annual CFI of BCRX is $52.59 M

What is the all time high annual CFI for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals all-time high annual cash flow from investing activities is $77.93 M

What is BioCryst Pharmaceuticals annual CFI year-on-year change?

Over the past year, BCRX annual cash flow from investing activities has changed by +$184.09 M (+140.00%)

What is BioCryst Pharmaceuticals quarterly cash flow from investing activities?

The current quarterly CFI of BCRX is $17.80 M

What is the all time high quarterly CFI for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals all-time high quarterly cash flow from investing activities is $77.22 M

What is BioCryst Pharmaceuticals quarterly CFI year-on-year change?

Over the past year, BCRX quarterly cash flow from investing activities has changed by $0.00 (0.00%)

What is BioCryst Pharmaceuticals TTM cash flow from investing activities?

The current TTM CFI of BCRX is $52.59 M

What is the all time high TTM CFI for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals all-time high TTM cash flow from investing activities is $77.93 M

What is BioCryst Pharmaceuticals TTM CFI year-on-year change?

Over the past year, BCRX TTM cash flow from investing activities has changed by $0.00 (0.00%)